Phase III pivotal study of NKTR-214 plus Opdivo (nivolumab) in patients with advanced melanoma
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2018
At a glance
- Drugs Nivolumab (Primary) ; NKTR 214 (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- 02 Jun 2018 This trial is expected to be initiated in Q3 2018, according to the Nektar Therapeutics media release.
- 09 Mar 2018 New trial record
- 01 Mar 2018 According to the Nektar Therapeutics media release, this study is to be initiated in mid-2018.